

Sacral Neuromodulation: Emerging Technologies and Rehabilitation Implications

¹Asha Mohan

Introduction

Lower urinary tract and bowel dysfunctions are common causes of disability and reduced quality of life. Although behavioural interventions, pelvic floor rehabilitation, and pharmacotherapy remain first-line treatments, a significant proportion of patients continue to experience persistent symptoms despite adequate conservative management.^{1,2} Sacral neuromodulation (SNM) has become an established treatment for refractory overactive bladder (OAB), urgency urinary incontinence, non-obstructive urinary retention, and faecal incontinence.³

Since its introduction in the late 1980s, SNM has evolved from a niche therapy into a sophisticated neuromodulation platform supported by improved device technology and expanding clinical evidence. Modern understanding suggests that SNM exerts its effects primarily through modulation of abnormal afferent signalling within sacral and supraspinal neural pathways involved in continence control rather than through direct stimulation of bladder contraction alone.⁴ Functional neuroimaging studies demonstrating altered cortical and subcortical activity following stimulation further support a role for central neuroplasticity in mediating therapeutic benefit.⁵

Expanding Clinical Applications

While OAB and urinary retention remain the most common indications, the scope of SNM continues to broaden. Growing evidence supports its use in selected patients with neurogenic lower urinary tract dysfunction, particularly those with multiple sclerosis

incomplete spinal cord injury.⁶ The therapy has also demonstrated durable efficacy in faecal incontinence, improving continence scores and quality of life in appropriately selected patients.⁷

Emerging applications include chronic pelvic pain, constipation, incontinence, and selected neurological disorders. Although current evidence remains limited for these indications, ongoing studies suggest that neuro-modulation may have a wider role in functional pelvic disorders than previously recognized.⁸ [Table 1]

Table 1. Established and Emerging Indications

Established Indications	Emerging Applications
Overactive bladder	Chronic pelvic pain
Urgency urinary incontinence	Constipation
Non-obstructive urinary retention	Neurogenic bladder dysfunction
Faecal incontinence	
Urgency-frequency syndrome	

Technological Advances and Outcomes

Technological innovation represents the most significant development in SNM during the last decade. Rechargeable implantable pulse generators have substantially increased battery longevity,

Reducing the need for replacement surgeries and improving long-term cost efficiency.⁹ MRI-compatible systems have addressed a major limitation of earlier devices, allowing patients to safely undergo magnetic resonance imaging when clinically indicated.⁹ Advances in lead design, including tined leads and improved anchoring systems, have reduced lead migration and revision rates. Device miniaturization has improved patient comfort and cosmetic acceptability, while remote programming and telemedicine-based follow-up have facilitated

¹Government Medical College Konni

Address for correspondence Dr Asha Mohan MBBS, MD DNB PMR, FIPM, Assistant Professor Dept of PMR Government Medical College, Konni
Email: asha.mohanan777@gmail.com

optimization of stimulation parameters with fewer hospital visits.¹⁰

Research is increasingly focused on adaptive or closed-loop neuromodulation systems capable of automatically adjusting stimulation according to physiological feedback signals. Such technologies may improve therapeutic precision and energy efficiency. Artificial intelligence-based approaches are also being investigated for predicting treatment response and individualizing programming parameters.¹¹

Clinical outcomes remain highly favourable. Long-term studies report sustained success rates of approximately 70–80% in patients with refractory OAB, with benefits extending beyond five years in many cohorts.¹² Patients with non-obstructive urinary retention frequently achieve restoration of spontaneous voiding and reduced dependence on intermittent catheterization.¹³ Similar improvements in continence and quality of life have been reported among patients treated for faecal incontinence.⁷

Comparative studies indicate that SNM provides greater durability than percutaneous tibial nerve stimulation (PTNS), although PTNS remains less invasive. In comparison with intra-detrusor botulinum toxin injections, SNM offers sustained continuous therapy while avoiding the need for repeated injections and reducing the risk of treatment-related urinary retention.² Consequently, treatment selection should be individualized according to patient characteristics, comorbidities, treatment goals, and resource availability.

Comparative studies indicate that SNM provides greater durability than percutaneous tibial nerve stimulation (PTNS), although PTNS remains less invasive. In comparison with intra-detrusor botulinum toxin injections, SNM offers sustained continuous therapy while avoiding the need for repeated injections and reducing the risk of treatment-related urinary retention.² Consequently, treatment selection should be individualized according to patient characteristics, comorbidities, treatment goals, and resource availability.

Table 2. Comparison of Third-Line Therapies for OAB

Parameter	SNM	PTNS	Botulinum
Efficacy	High	Moderate	High
Durability	Long-term	Maintenance required	Temporary
Repeat procedures	Infrequent	Frequent	Repeated injections
Urinary retention risk	Low	Minimal	Higher

Rehabilitation Implications and Future Directions

SNM has increasing relevance within neuro-urological rehabilitation. Restoration of continence and improved bladder emptying can significantly enhance independence, social participation, caregiver burden, and overall quality of life in patients with neurological disorders.⁶ Integration of neuromodulation with pelvic floor rehabilitation, behavioural therapies, and multidisciplinary rehabilitation programs may further optimize functional outcomes.

Future developments are expected to focus on precision neuromodulation, wearable monitoring technologies, adaptive closed-loop stimulation, and artificial intelligence-assisted treatment selection.¹¹ These advances may facilitate individualized therapy, improve long-term outcomes, and expand the role of SNM in functional restoration and neurorehabilitation.

Conclusion

Sacral neuromodulation has evolved into a mature neuromodulation platform with expanding indications and increasingly sophisticated technology. Rechargeable systems, MRI compatibility, miniaturization, remote programming, and emerging adaptive stimulation strategies have improved safety, durability, and patient experience. As evidence continues to grow, SNM is likely to play an increasingly important role in the personalized management of bladder, bowel, and pelvic floor dysfunction, particularly within neuro-urological rehabilitation.

References

1. Feloney MP, Stauss K, Leslie SW. Sacral Neuromodulation. StatPearls Publishing; 2024.
2. Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. *Res Rep Urol*. 2016;8:193–199.
3. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. *J Urol*. 1988;140(6):1331–1339.
4. Banakhar MA, Al-Shaiji T, Hassouna M. Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem. *Ther Adv Urol*. 2012;4(4):179–185.
5. Kessler TM, Buchser E, Meyer S, et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: clinical outcomes and functional brain imaging. *Eur Urol*. 2008;53(6):1184–1191.
6. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology Guidelines on Neuro-Urology. *Eur Urol*. 2016;69(2):324–333.
7. Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. *Lancet*. 1995;346(8983):1124–1127.
8. Jairam R, Marcelissen T, van Koeveeringe G. Predictive factors in sacral neuromodulation: a systematic review. *Urol Int*. 2022;106(4):323–343.
9. Blok B, van Kerrebroeck P, de Wachter S. Advances in sacral neuromodulation therapy. *Curr Opin Urol*. 2024;34(1):45–52.
10. Goldman HB, Lloyd JC, Noblett KL, et al. International Continence Society best practice statement for sacral neuromodulation. *Neurourol Urodyn*. 2020;39(7):1823–1848.
11. Peeters K, Sahai A, De Wachter S. Future neuromodulation technologies and artificial intelligence applications. *Neurourol Urodyn*. 2023;42(6):1456–1464.
12. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for urinary urge incontinence. *J Urol*. 2000;163(4):1219–1222.
13. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary retention. *J Urol*. 1999;162(2):352–357